Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tositumomab and Iodine-131 Tositumomab in Relapsed Indolent NHL Post-Rituximab
NCT00240565Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2004
- Primary completion
- Feb 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tositumomab, iodine i 131 tositumomab in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by GSK. Started Apr 2004; status: completed.
02
Drugs
tositumomabiodine i 131 tositumomab
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT00240565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00240565.